Serum biomarkers for differential diagnosis of adnexal masses in pregnant and nonpregnant women
- Authors: Martynov SA1
-
Affiliations:
- ФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава России, Москва
- Issue: Vol 16, No 4 (2014)
- Pages: 63-67
- Section: Articles
- URL: https://journals.rcsi.science/2079-5831/article/view/28378
- ID: 28378
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
S A Martynov
ФГБУ Научный центр акушерства, гинекологии и перинатологии им. акад. В.И.Кулакова Минздрава России, Москва
Email: samartynov@mail.ru
канд. мед. наук, ст. науч. сотр. гинекологического отд-ния
References
- Адамян Л.В., Мурашко Л.Е., Романова Е.Л. Хирургическое лечение опухолей и опухолевидных образований яичников у беременных с использованием современных технологий. Проблемы репродукции. 2005; 3: 60-4.
- Алексеева М.Л., Гусарова Е.В., Муллабаева С.М., Понкратов Т.С. Онкомаркеры, их характеристика и некоторые аспекты клинико - диагностического использования. Проблемы репродукции. 2005; 3: 43-5.
- Ашрафян Л.А., Киселев В.И. Опухоли репродуктивной системы (этиология, патогенез). М.: Димитрейд График Групп, 2007.
- Бохман Я.В. Руководство по онкогинекологии. Л.: Медицина, 1989.
- Ильина Л.М. Рак яичников: новое в диагностике и лечении. Информационное письмо ассоциации гинекологов - эндокринологов России №11 от 30.04.2011.
- Краснопольский В.И., Логутова Л.С., Буянова С.Н. и др. Хирургическая и акушерская тактика при сочетании беременности с опухолями половых органов. Акуш. и гинекол. 2002; 5: 41-5.
- Магнитская Н.А. Диагностика и лечение образований яичников у беременных. Автореф. дис.. канд. мед. наук. М., 2012.
- Савельева Г.М., Бреусенко В.Г., Соломатина А.А. Диагностика опухолей и опухолевидных образований яичников. Рос. вестн. акушера - гинеколога. 2005; 6: 53-61.
- Серов В.Н., Кудрявцева Л.И. Доброкачественные опухоли и опухолевидные образования яичников. М: Триада-Х, 1999; 149.
- Урманчеева А.Ф., Кутушева Г.Ф., Ульрих Е.А. Опухоли яичника (клиника, диагностика и лечение). Спб.: Н-Л, 2012.
- Aggarwal P, Kehoe S. Ovarian tumors in pregnancy: a literature review. Eur J Obstet Gynecol Reprod Biol 2011; 155: 119-24.
- American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. Committee Opinion No. 477: the role of the obstetrician - gynecologist in the early detection of epithelial ovarian cancer. Obstet Gynecol 2011; 117: 742.
- American College of Obstetricians anf Gynecologists. ACOG Committee Opinion: number 280, December 2002. The role of the generalist obstetrician - gynecologist in the early detection of ovarian cancer. Obstet Gynecol 2002; 100: 1413.
- Anton C, Carvalho F.M, Oliveira E.I et al. A comparison of CA125, HE4, risk ovarian malignancy algorithm (ROMA), and risk malignancy index (RMI) for the classification of ovarian masses. Clinics 2012; 67: 437-41.
- Bast R.C.Jr, Skates S, Lokshin A, Moore R.G. Differential diagnosis of pelvic mass: improved algorithms and novel biomarkers. Int J Gynecol Cancer 2012; 22: 5-8.
- Behtash N, Karimi Zarchi M et al. Ovarian carcinoma associated with pregnancy: a clinicopathologic analysis of 23 cases and review of the literature. BMC Pregnancy Childbirth 2008; 8: 3-10.
- Chen L, Berek J.S, Goff B et al. Ovarian tumors of low malignant potential. http://www.uptodate.com /contents/
- Coskun A, Kiran G, Ozdemir O. CA 19-9 can be a useful tumor marker in ovarian dermoid cysts. Clin Exp Obstet Gynecol 2008; 35 (2): 137-9.
- Dodge J.E, Covens A.L, Lacchetti C et al. Preoperative identification of a suspicious adnexal mass: a systematic review and meta - analysis. Gynecol Oncol 2012; 126: 157.
- Drapkin R, von Horsten H.H, Lin Y et al. Human epididymis protein (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005; 65: 2162-9.
- Duffy M.J, Bonfrer J.M, Kulpa J et al. CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use. Int J Gynecol Cancer 2005; 15: 679.
- Fung E.T. A recipe for proteomics diagnostic test development: the OVA1 test, from biomarker discovery to FDA clearance. Clin Chem 2010; 56 (2): 327-9.
- Galgano M.T, Hampton G.M, Frierson H.F.Jr. Comprehensive analysis of HE4 expression in normal and malignant human tissues. Mod Pathol 2006; 19: 847-53.
- Geomini P, Kruitwagen R, Bremer G.L et al. The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol 2009; 113: 384.
- Hakansson F, Hodgall E.V, Nedergaard L et al. Risk of malignancy index used as a diagnostic tool in a tertiary centre for patients with pelvic mass. Acta Obstet Gynecol Scand 2012; 91: 496-502.
- Hellström I, Raycraft J, Hayden-Ledbetter M et al. The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma. Cancer Res 2003; 63: 3695-700.
- Hoover K, Jenkins T.R. Evaluation and management of adnexal mass in pregnancy. Am J Obstet Gynecol 2011; 97-102.
- Huhtinen K, Suvitie P, Hiissa J et al. Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts. Br J Cancer 2009; 100: 1315-9.
- Jemal A, Bray F, Center M.M et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69.
- Kadija S, Stefanovic A, Jeremic K et al. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis. Int J Gynecol Cancer 2012; 22: 238-44.
- Karlsen M.A, Sandhu N, Hodgall C et al. Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer patients with pelvic mass. Gynecol Oncol 2012; 127: 379-83.
- Kim Y.M, Whang D.H, Park J et al. Evaluation of the accuracy of serum human epididymis protein 4 in combination with CA125 for detecting ovarian cancer: a prospective case - control study in a Korean population. Clin Chem Lab Med 2011; 49: 527-34.
- Kumari I, Kaur S, Mohan H, Huria A. Adnexal masses in pregnancy: a 5-year review. Aust N Z J Obstet Gynaecol 2006; 46: 52-4.
- Leiserowitz G, Xing G et al. Adnexal masses in pregnancy: how often are they malignant? Gynecol Oncol 2006; 101: 315-21.
- Lenhard M, Stieber P, Hertlein L et al. The diagnostic accuracy of two human epididymis protein 4 (HE4) testing systems in combination with CA125 in the differential diagnosis of ovarian masses. Clin Chem Lab Med 2011; 49: 2081-8.
- Lin J, Qin J, Sangvatanakul V. Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta - analysis. Eur J Obstet Gynecol Reprod Biol 2013; 167 (1): 81-5.
- Montagnana M, Danese E, Ruzzenente O et al. The ROMA (The Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful? Clin Chem Lab Med 2011; 49: 521-5.
- Moore L.E, Fung E.T, Mc Guire M et al. Evaluation of apolipoprotein A1 and posttranslationally modified forms of transthyretin as biomarkers for ovarian cancer detection in an independent study population. Cancer Epidemiol Biomarkers Prev 2006; 15: 1641.
Supplementary files
